Hospital
Kaiser Foundation Hospitals
Kaiser Foundation Hospitals was paid $19.06M by Medicaid between Jan 2018 and Dec 2024, across 314 billing codes. Its largest line is 99284, emergency room visit (serious) — 15% of everything it billed.
33Billing provider infoKAISER FOUNDATION HOSPITALS
VALLEJO, CA 94589
VALLEJO, CA 94589
33aNPI1366513509assigned 11/10/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$19.06M
24GClaims1,577,036
24DCodes billed314
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in California
Rank by total paid#129 of 410
Median peer was paid$6.90M
This provider vs. median2.8×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 99,067 | $982K | |
| 2019 | 149,877 | $979K | |
| 2020 | 178,411 | $1.00M | |
| 2021 | 279,309 | $1.28M | |
| 2022 | 344,760 | $1.59M | |
| 2023 | 345,338 | $1.66M | |
| 2024incomplete | 180,274 | $11.57M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 15% | 19,412 | 18,093 | $2.93M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 12% | 31,149 | 28,037 | $2.26M |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | 9.5% | 45,091 | 40,727 | $1.82M |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 7.6% | 24,921 | 23,796 | $1.45M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 6.6% | 5,752 | 5,392 | $1.25M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 4.6% | 9,302 | 9,137 | $882K |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | 3.0% | 13,256 | 12,555 | $574K |
| 70450 | Computed tomography, head or brain; without contrast material | 2.2% | 8,837 | 8,531 | $420K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 1.6% | 30,033 | 27,561 | $314K |
| 71045 | Radiologic examination, chest; single view | 1.6% | 21,336 | 19,996 | $309K |
| 71046 | Radiologic examination, chest; 2 views | 1.2% | 16,092 | 15,724 | $226K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 1.2% | 15,805 | 14,569 | $224K |
302 more codes
| 70551 | Magnetic resonance imaging, brain; without contrast material | 1.0% | 3,566 | $195K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 3,891 | $179K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 16,388 | $174K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 8,459 | $172K |
| 0450 | Emergency room services | <1% | 3,945 | $157K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 80,811 | $156K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 5,101 | $153K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 3,437 | $152K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 7,027 | $140K |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 9,986 | $127K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 12,145 | $126K |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 3,041 | $121K |
| 73564 | <1% | 5,207 | $115K | |
| 78815 | Positron emission tomography (PET) for limited area imaging | <1% | 56 | $111K |
| 80051 | <1% | 54,270 | $109K | |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 6,070 | $99K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 11,520 | $91K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 9,334 | $87K |
| 76830 | Ultrasound, transvaginal | <1% | 5,633 | $87K |
| 73630 | <1% | 6,677 | $85K | |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 1,610 | $84K |
| 82565 | <1% | 66,116 | $84K | |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 1,865 | $84K |
| 73610 | <1% | 5,871 | $82K | |
| 99070 | <1% | 15,412 | $82K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 987 | $80K |
| 76642 | <1% | 2,959 | $78K | |
| 73130 | <1% | 5,155 | $74K | |
| J3490 | Unclassified drugs | <1% | 30,622 | $74K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 4,610 | $72K |
| 73030 | <1% | 4,928 | $70K | |
| 83880 | <1% | 9,441 | $68K | |
| 72141 | <1% | 1,890 | $66K | |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 3,327 | $64K |
| 77065 | Tomosynthesis, mammo | <1% | 1,298 | $61K |
| 72100 | <1% | 3,887 | $61K | |
| 82947 | <1% | 55,270 | $59K | |
| 70486 | <1% | 1,263 | $59K | |
| 76770 | <1% | 2,440 | $58K | |
| 80306 | <1% | 7,144 | $57K | |
| 84520 | <1% | 55,773 | $56K | |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 2,250 | $55K |
| G0378 | Hospital observation service, per hour | <1% | 891 | $53K |
| 74018 | <1% | 3,508 | $53K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 3,765 | $51K |
| 93971 | <1% | 1,775 | $51K | |
| 83690 | <1% | 25,500 | $51K | |
| 77066 | Tomosynthesis, mammo | <1% | 1,152 | $50K |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 21,116 | $50K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 3,764 | $50K |
| 73110 | <1% | 4,200 | $48K | |
| 82247 | <1% | 38,008 | $47K | |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 413 | $46K |
| 36415 | Collection of venous blood by venipuncture | <1% | 9,908 | $44K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 8,658 | $44K |
| 84460 | <1% | 37,493 | $43K | |
| 84484 | <1% | 15,374 | $43K | |
| 84450 | <1% | 33,478 | $40K | |
| 71250 | <1% | 1,498 | $40K | |
| 73502 | <1% | 2,568 | $39K | |
| 76882 | <1% | 1,179 | $38K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 2,074 | $38K |
| 76536 | <1% | 1,689 | $36K | |
| 77080 | <1% | 2,190 | $36K | |
| 73140 | <1% | 2,982 | $35K | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 973 | $35K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 15,142 | $34K |
| 87631 | <1% | 862 | $33K | |
| 73560 | <1% | 3,118 | $33K | |
| 84075 | <1% | 29,200 | $33K | |
| 99199 | Unlisted special service, procedure or report | <1% | 563 | $31K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 3,123 | $29K |
| 81001 | <1% | 53,897 | $29K | |
| 87040 | <1% | 5,730 | $28K | |
| 82077 | <1% | 4,850 | $28K | |
| 72040 | <1% | 2,175 | $28K | |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 383 | $27K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 2,511 | $27K |
| 73590 | <1% | 2,091 | $27K | |
| 83735 | <1% | 15,171 | $27K | |
| 73080 | <1% | 2,287 | $26K | |
| 70491 | <1% | 667 | $25K | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 1,216 | $21K |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 12,729 | $21K |
| 86900 | <1% | 4,890 | $20K | |
| 83605 | <1% | 5,909 | $20K | |
| 87088 | <1% | 8,763 | $19K | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 10,690 | $18K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 7,923 | $17K |
| 74022 | <1% | 1,431 | $17K | |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 2,048 | $17K |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 5,836 | $17K |
| 73221 | <1% | 885 | $17K | |
| 84702 | <1% | 9,217 | $16K | |
| 93976 | <1% | 792 | $16K | |
| A9552 | Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | <1% | 107 | $15K |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 8,111 | $14K |
| 82803 | <1% | 1,419 | $12K | |
| 76870 | <1% | 632 | $12K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 939 | $12K |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 4,191 | $11K |
| 81003 | <1% | 27,691 | $11K | |
| 85610 | <1% | 13,334 | $11K | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 4,476 | $11K |
| 82962 | <1% | 13,439 | $11K | |
| 59025 | Fetal non-stress test | <1% | 2,393 | $10K |
| G0151 | Services performed by a qualified physical therapist in the home health or hospice setting, each 15 minutes | <1% | 6,760 | $9K |
| 71101 | <1% | 716 | $9K | |
| 86850 | <1% | 3,915 | $9K | |
| 84100 | <1% | 7,194 | $9K | |
| 80179 | <1% | 1,832 | $9K | |
| G0152 | Services performed by a qualified occupational therapist in the home health or hospice setting, each 15 minutes | <1% | 1,749 | $9K |
| 76857 | <1% | 926 | $9K | |
| C9290 | Injection, bupivacaine liposome, 1 mg | <1% | 261 | $8K |
| 82248 | <1% | 6,165 | $8K | |
| 86901 | <1% | 4,903 | $8K | |
| 72070 | <1% | 949 | $8K | |
| 85652 | <1% | 16,022 | $8K | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 913 | $7K |
| 0270 | <1% | 1,025 | $7K | |
| J1815 | Injection, insulin, per 5 units | <1% | 4,563 | $7K |
| 85027 | <1% | 5,630 | $6K | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 4,418 | $6K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 2,239 | $6K |
| 73090 | <1% | 1,455 | $6K | |
| A9575 | Injection, gadoterate meglumine, 0.1 ml | <1% | 624 | $6K |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 3,820 | $5K |
| 90715 | <1% | 216 | $5K | |
| 84132 | <1% | 6,336 | $5K | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 2,025 | $5K |
| P9016 | Red blood cells, leukocytes reduced, each unit | <1% | 50 | $5K |
| 82310 | <1% | 4,366 | $4K | |
| 73660 | <1% | 799 | $4K | |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 2,181 | $4K |
| 84703 | <1% | 8,418 | $4K | |
| 93923 | <1% | 55 | $4K | |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 18 | $4K |
| 74019 | <1% | 825 | $4K | |
| 86140 | <1% | 2,553 | $4K | |
| 0637 | <1% | 15,859 | $3K | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 3,601 | $3K |
| 97162 | <1% | 178 | $3K | |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 2,997 | $3K |
| 86923 | <1% | 396 | $3K | |
| J1940 | Injection, furosemide, up to 20 mg | <1% | 1,491 | $3K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 1,913 | $3K |
| 87070 | <1% | 1,256 | $3K | |
| 73060 | <1% | 382 | $3K | |
| 93970 | <1% | 207 | $3K | |
| 96367 | <1% | 306 | $3K | |
| G0299 | Direct skilled nursing services of a registered nurse (rn) in the home health or hospice setting, each 15 minutes | <1% | 4,403 | $3K |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 5,323 | $3K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 157 | $3K |
| 82570 | <1% | 1,766 | $3K | |
| 87324 | <1% | 1,444 | $3K | |
| 87449 | <1% | 1,465 | $3K | |
| 86780 | <1% | 643 | $3K | |
| 82040 | <1% | 3,222 | $2K | |
| 72170 | <1% | 523 | $2K | |
| 85379 | <1% | 1,640 | $2K | |
| 73700 | <1% | 97 | $2K | |
| 84295 | <1% | 3,038 | $2K | |
| 74183 | <1% | 282 | $2K | |
| 87081 | <1% | 1,464 | $2K | |
| J3480 | Injection, potassium chloride, per 2 meq | <1% | 216 | $2K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 3,606 | $2K |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 713 | $2K |
| G0153 | Services performed by a qualified speech-language pathologist in the home health or hospice setting, each 15 minutes | <1% | 69 | $2K |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 1,196 | $2K |
| J1953 | Injection, levetiracetam, 10 mg | <1% | 229 | $2K |
| 73552 | <1% | 435 | $2K | |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 940 | $2K |
| 85378 | <1% | 1,261 | $2K | |
| 76775 | <1% | 443 | $2K | |
| 87210 | <1% | 1,144 | $2K | |
| A9585 | Injection, gadobutrol, 0.1 ml | <1% | 1,114 | $2K |
| 82550 | <1% | 1,158 | $2K | |
| 73562 | <1% | 1,270 | $2K | |
| 84156 | <1% | 1,494 | $2K | |
| 83615 | <1% | 1,484 | $2K | |
| 80047 | <1% | 478 | $1K | |
| 82140 | <1% | 733 | $1K | |
| 96376 | <1% | 391 | $1K | |
| 72146 | <1% | 78 | $1K | |
| 80061 | Lipid panel | <1% | 653 | $1K |
| J2274 | Injection, morphine sulfate, preservative-free for epidural or intrathecal use, 10 mg | <1% | 35 | $1K |
| 80069 | <1% | 467 | $1K | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 3,838 | $1K |
| 0250 | <1% | 1,998 | $1K | |
| 73522 | <1% | 335 | $1K | |
| 85730 | <1% | 1,866 | $1K | |
| 90686 | <1% | 190 | $984.28 | |
| J3370 | Injection, vancomycin hcl, 500 mg | <1% | 437 | $929.70 |
| 85007 | <1% | 786 | $929.24 | |
| 73600 | <1% | 190 | $926.38 | |
| J3371 | Injection, vancomycin hcl (mylan), not therapeutically equivalent to j3370, 500 mg | <1% | 139 | $884.93 |
| G0155 | Services of clinical social worker in home health or hospice settings, each 15 minutes | <1% | 500 | $844.27 |
| 85014 | <1% | 1,773 | $798.76 | |
| 87340 | <1% | 570 | $797.00 | |
| 70543 | <1% | 56 | $704.46 | |
| 72220 | <1% | 38 | $587.00 | |
| 82728 | <1% | 433 | $568.55 | |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | <1% | 209 | $486.88 |
| 88307 | <1% | 479 | $478.53 | |
| 85045 | <1% | 474 | $453.04 | |
| 88304 | <1% | 825 | $451.89 | |
| 87205 | <1% | 688 | $450.05 | |
| 88342 | <1% | 540 | $444.40 | |
| 72050 | <1% | 86 | $431.95 | |
| 86803 | <1% | 215 | $420.04 | |
| 76801 | <1% | 26 | $402.52 | |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 421 | $397.41 |
| 96368 | <1% | 109 | $390.42 | |
| 84550 | <1% | 669 | $390.24 | |
| 73620 | <1% | 180 | $362.75 | |
| J1756 | Injection, iron sucrose, 1 mg | <1% | 4,719 | $344.39 |
| 83540 | <1% | 641 | $320.98 | |
| 88341 | <1% | 166 | $320.75 | |
| 89051 | <1% | 369 | $302.08 | |
| 72082 | <1% | 41 | $292.82 | |
| 73000 | <1% | 84 | $282.68 | |
| J0360 | Injection, hydralazine hcl, up to 20 mg | <1% | 156 | $276.65 |
| S0119 | Ondansetron, oral, 4 mg (for circumstances falling under the medicare statute, use hcpcs q code) | <1% | 363 | $271.93 |
| 73100 | <1% | 60 | $262.04 | |
| 73120 | <1% | 106 | $259.53 | |
| 83550 | <1% | 404 | $257.59 | |
| J2543 | Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams) | <1% | 97 | $253.59 |
| 80053 | Comprehensive metabolic panel | <1% | 1,026 | $243.64 |
| 10060 | <1% | 12 | $225.79 | |
| Z7502 | <1% | 28 | $220.10 | |
| J3360 | Injection, diazepam, up to 5 mg | <1% | 61 | $213.40 |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | <1% | 322 | $173.89 |
| 85018 | <1% | 1,267 | $169.32 | |
| 84155 | <1% | 327 | $136.96 | |
| 76000 | <1% | 92 | $130.35 | |
| 76942 | <1% | 79 | $113.78 | |
| J1836 | Injection, metronidazole, 10 mg | <1% | 157 | $109.73 |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 326 | $100.38 |
| 93017 | <1% | 38 | $97.90 | |
| 83970 | <1% | 272 | $90.58 | |
| J7042 | 5% dextrose/normal saline (500 ml = 1 unit) | <1% | 49 | $84.93 |
| J8540 | Dexamethasone, oral, 0.25 mg | <1% | 312 | $80.69 |
| 12011 | <1% | 13 | $67.12 | |
| 29125 | <1% | 24 | $65.24 | |
| 86704 | <1% | 25 | $62.54 | |
| 86706 | <1% | 65 | $62.31 | |
| A4927 | Gloves, non-sterile, per 100 | <1% | 55 | $54.33 |
| 82150 | <1% | 103 | $53.98 | |
| 85008 | <1% | 245 | $49.47 | |
| 86703 | <1% | 15 | $46.65 | |
| J1630 | Injection, haloperidol, up to 5 mg | <1% | 45 | $46.64 |
| C9113 | Injection, pantoprazole sodium, per vial | <1% | 361 | $45.68 |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 28 | $34.08 |
| 82435 | <1% | 54 | $33.66 | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 12 | $32.23 |
| 80349 | <1% | 41 | $31.00 | |
| 85384 | <1% | 44 | $29.76 | |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | <1% | 14 | $29.42 |
| 82272 | <1% | 92 | $24.75 | |
| J3411 | Injection, thiamine hcl, 100 mg | <1% | 13 | $20.84 |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 576 | $20.77 |
| 76937 | <1% | 13 | $20.49 | |
| J1270 | Injection, doxercalciferol, 1 mcg | <1% | 9,476 | $18.40 |
| J0744 | Injection, ciprofloxacin for intravenous infusion, 200 mg | <1% | 46 | $16.52 |
| 83930 | <1% | 42 | $15.28 | |
| 82374 | <1% | 52 | $15.24 | |
| J8501 | Aprepitant, oral, 5 mg | <1% | 274 | $10.44 |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 878 | $10.07 |
| 83935 | <1% | 12 | $7.83 | |
| Q0144 | Azithromycin dihydrate, oral, capsules/powder, 1 gram | <1% | 15 | $6.42 |
| 81025 | <1% | 13 | $5.22 | |
| A6216 | Gauze, non-impregnated, non-sterile, pad size 16 sq. in. or less, without adhesive border, each dressing | <1% | 53 | $5.06 |
| 88300 | <1% | 68 | $4.34 | |
| J2470 | Injection, pantoprazole sodium, 40 mg | <1% | 20 | $3.87 |
| 90945 | 0% | 1,795 | $0.00 | |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | 0% | 798 | $0.00 |
| 84466 | 0% | 31 | $0.00 | |
| 90999 | Dialysis (unlisted procedure) | 0% | 38,523 | $0.00 |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 0% | 316 | $0.00 |
| 97116 | 0% | 232 | $0.00 | |
| 76376 | 0% | 117 | $0.00 | |
| 90662 | 0% | 44 | $0.00 | |
| J0137 | Injection, acetaminophen (hikma), not therapeutically equivalent to j0131, 10 mg | 0% | 18 | $0.00 |
| 87899 | 0% | 12 | $0.00 | |
| 0300 | 0% | 13 | $0.00 | |
| Q5001 | Hospice or home health care provided in patient's home/residence | 0% | 617 | $0.00 |
| A4657 | Syringe, with or without needle, each | 0% | 15,665 | $0.00 |
| 66984 | Extracapsular cataract removal with insertion of intraocular lens prosthesis | 0% | 143 | $0.00 |
| G0156 | Services of home health/hospice aide in home health or hospice settings, each 15 minutes | 0% | 1,226 | $0.00 |
| V2632 | Posterior chamber intraocular lens | 0% | 317 | $0.00 |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | 0% | 64 | $0.00 |
| 90677 | 0% | 18 | $0.00 | |
| 90694 | 0% | 24 | $0.00 | |
| 0100 | 0% | 43 | $0.00 | |
| 87086 | Culture, bacterial; quantitative colony count, urine | 0% | 13 | $0.00 |
| A5120 | Skin barrier, wipes or swabs, each | 0% | 14 | $0.00 |
| 12001 | 0% | 12 | $0.00 | |
| 90674 | 0% | 34 | $0.00 | |
| 74181 | 0% | 13 | $0.00 | |
| 70544 | 0% | 13 | $0.00 | |
| 81015 | 0% | 29 | $0.00 | |
| G0300 | Direct skilled nursing services of a licensed practical nurse (lpn) in the home health or hospice setting, each 15 minutes | 0% | 225 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialJEMJEMIAN, NORAIR (SENIOR VICE PRESIDENT/AREA MANAGER)
| Provider | Location | Paid |
|---|---|---|
| Kaiser Foundation Hospitals | Vacaville, CA | $10.07M |
| Kaiser Foundation Hospitals | Vallejo, CA | $817K |
| Kaiser Foundation Hospitals | Vallejo, CA | $18K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.